Community

Matt Killeen, Ph.D.

Chief Scientific Officer, Renovacor

Matt Killeen, Ph.D., is the Chief Scientific Officer at Renovacor. Prior to joining Renovacor, Dr. Killeen served as the head of cardiovascular research at BioMarin Pharmaceutical Inc., where he led the discovery and early development of novel AAV-based gene therapies for a range of inherited heart diseases. Before BioMarin, Dr. Killeen led efforts to support the commercialization and launch of new therapies for multiple sclerosis at Biogen. He holds a Ph.D. in cardiac electrophysiology from the University of Cambridge and has published more than 20 peer-reviewed papers on topics spanning genetic cardiac diseases, cardiac electrophysiology, arrhythmias and drug safety.

Community

Matt Killeen, Ph.D.

Chief Scientific Officer, Renovacor

Contributions

Q: For what therapeutic area do you think we will see the greatest progress in the coming years?